Evaluating stem cells in myelodysplastic syndromes using advanced flow cytometry

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to assess the predictive value of myelodysplastic syndrome stem cells (MDS-SC) in patients with myelodysplastic syndromes (MDS) undergoing allogeneic stem cell transplantation. Utilizing multiparameter flow cytometry (MFC), the study will investigate how effectively MDS-SC can predict patient outcomes post-transplantation. The research will be conducted across multiple centers, enhancing the reliability of the findings. The goal is to improve disease monitoring and treatment strategies for MDS patients.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients with Myelodysplastic syndromes;
* Between 15 and 70 years old;
* Subjects are able to provide written informed consent.

Exclusion Criteria:

* Subjects who cannot comply with the study;
* Patient has severe cardiac (ejection fraction \<50%), hepatic (total bilirubin \>34μmol/L, ALT, AST \>2x upper limit of normal) or renal (blood creatinine \>130μmol/L) disease；
* Uncontrolled serious infection;
* Other conditions that do not tolerate transplantation or other therapies.

Where it's running

• Chinese PLA General Hospital
  Beijing, China Recruiting
• Peking University People's Hospital
  Beijing, China Recruiting
• Wuhan TongJi Hospital
  Wuhan, China Recruiting
• The First Affiliated Hospital of Zhengzhou University
  Zhengzhou, China Recruiting

Study contacts

• Study coordinator: chief physician
• Email: rmcyj@bjmu.edu.cn
• Phone: 13520536738

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Age-stratified conditioning regimens to improve outcomes in haploidentical stem cell transplant for myelodysplastic syndrome

  This study tests two conditioning regimens in adults with MDS undergoing haploidentical stem cell transplant to see how age affects outcomes over one year.

  Recruiting Phase 2 Peking University People's Hospital · Beijing · NCT07677306

• FXS0683 in relapsed or refractory blood cancers

  This first‑in‑human study tests FXS0683 in adults with relapsed or refractory B‑cell lymphoma, AML, MDS, or ALL to see if it is safe, how the drug behaves in the body, and whether it shows any antitumor activity.

  Recruiting Phase 1 Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. · Tianjin, Tianjin Municipality · NCT07616089

• Brain network changes in adults with anemia measured by fNIRS

  This project will use functional near-infrared spectroscopy (fNIRS) to see if brain network connections are altered in adults aged 18–65 who have anemia.

  Recruiting Institute of Hematology & Blood Diseases Hospital, China · Tianjin, Tianjin Municipality · NCT07578675

• Cord blood transplant for children and young adults with blood cancers.

  This study will test whether a cord blood transplant given as a first or second transplant can help children and young adults with leukemia, myelodysplasia, or lymphoma who lack a matched donor.

  Recruiting Phase 2 Memorial Sloan Kettering Cancer Center · New York, New York · NCT07566377

• Reduced-intensity donor stem cell transplant with treosulfan/fludarabine and post-transplant cyclophosphamide for leukemia and MDS

  This trial tests a lower-intensity donor stem cell transplant using treosulfan plus fludarabine with post-transplant cyclophosphamide to try to reduce toxicity and prevent graft-versus-host disease in people aged 2–75 with acute leukemias or myelodysplastic syndromes.

  Recruiting Phase 2 Masonic Cancer Center, University of Minnesota · Minneapolis, Minnesota · NCT07493538

• Electronic mindfulness-based music therapy for patients receiving stem cell transplantation

  This trial tests an eHealth mindfulness-based music therapy to see if it improves quality of life and reduces symptoms for adults undergoing stem cell transplantation.

  Recruiting University of Miami · Miami, Florida · NCT07469592

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.